REPL Stock Analysis: Replimune | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.424m USD | 12M Return: 179.8% | US76029N1063 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.6M
Qual. Beats: 0
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to activate the immune system against cancer. Its lead candidate, RP1, is a selectively replicating HSV-1-based therapy expressing GALV-GP R(-) and human GM-CSF, being studied across a range of solid tumors. The pipeline also includes RP2, which expresses an anti-CTLA-4 antibody-like protein, and RP3, which incorporates immune-activating proteins to stimulate T cells. Founded in 2015 and headquartered in Woburn, Massachusetts, the company listed on NASDAQ in 2018 under the ticker REPL.
As a clinical-stage biotech, Replimune is pre-commercial and relies on capital markets and partnerships to fund its research and development activities, with product revenue not expected until any candidates receive regulatory approval. Oncolytic immunotherapy is a specialized subset of the broader oncology drug development field, in which modified viruses are engineered to selectively infect and destroy tumor cells while stimulating an anti-cancer immune response.
- RP1 CERPASS trial readout in cutaneous squamous cell carcinoma
- FDA reviews RP1 BLA submission for advanced melanoma
- Replimune cash burn forces follow-on equity offering
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.85 > 0.02 and ΔFCF/TA -45.87 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.84 > 3% & CFO -280.3m > Net Income -313.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.8m) vs 12m ago 15.19% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.27%; Δ -0.27% > 0%) |
| Interest Coverage Ratio: -35.50 > 6 (EBIT TTM -314.5m / Interest Expense TTM 8.86m) |
| A: 0.66 (Total Current Assets 279.1m - Total Current Liabilities 58.2m) / Total Assets 332.4m |
| B: -3.80 (Retained Earnings -1.26b / Total Assets 332.4m) |
| C: -0.71 (EBIT TTM -314.5m / Avg Total Assets 441.9m) |
| D: 1.00 (Book Value of Equity 166.2m / Total Liabilities 166.2m) |
| Altman-Z'' = -11.76 = D |
As of August 16, 2026, the stock is trading at USD 14.97 with a total of 2,346,670 shares traded. Over the past week, the price has changed by +24.13%, over one month by +51.67%, over three months by +203.65% and over the past year by +179.81%.
Current recommended Stop Loss: 13.40 (which is 10.5% or 1 ATR below the current price).
Replimune has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy REPL.
- StrongBuy: 3
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.3 | 29.1% |
P/B = 6.9128
Revenue TTM = 0.0 USD
EBIT TTM = -314.5m USD
EBITDA TTM = -311.2m USD
Long Term Debt = 83.3m USD (from longTermDebt, last quarter)
Short Term Debt = 4.04m USD (from shortTermDebt, last quarter)
Debt = 139.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 28.3m
Net Debt = -129.0m USD (calculated: Debt 139.9m - CCE 268.9m)
Enterprise Value = 1.29b USD (1.42b + Debt 139.9m - CCE 268.9m)
Interest Coverage Ratio = -35.50 (Ebit TTM -314.5m / Interest Expense TTM 8.86m)
EV/FCF = -4.59x (Enterprise Value 1.29b / FCF TTM -282.3m)
FCF Yield = -21.81% (FCF TTM -282.3m / Enterprise Value 1.29b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.90 (Enterprise Value 1.29b / Total Assets 332.4m)
Interest Expense / Debt = 6.33% (Interest Expense 8.86m / Debt 139.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -248.4m (EBIT -314.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.30 (Total Current Assets 279.1m / Total Current Liabilities 64.9m)
Debt / Equity = 0.84 (Debt 139.9m / totalStockholderEquity, last quarter 166.2m)
Debt / EBITDA = 0.41 (negative EBITDA) (Net Debt -129.0m / EBITDA -311.2m)
Debt / FCF = 0.46 (negative FCF - burning cash) (Net Debt -129.0m / FCF TTM -282.3m)
Total Stockholder Equity = 244.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -71.05% (Net Income -313.9m / Total Assets 332.4m)
RoE = -128.6% (Net Income TTM -313.9m / Total Stockholder Equity 244.2m)
RoCE = -96.03% (EBIT -314.5m / Capital Employed (Equity 244.2m + L.T.Debt 83.3m))
RoIC = -89.31% (negative operating profit) (NOPAT -248.4m / Invested Capital 278.2m)
WACC = 15.26% (E(1.42b)/V(1.56b) * Re(16.27%) + D(139.9m)/V(1.56b) * Rd(6.33%) * (1-Tc(0.21)))
Discount Rate = 16.27% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 94.03 | Cagr: 15.85%
[DCF] Fair Price = unknown (Cash Flow -282.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.77 | Chg30d=-40.92% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.77 | Chg30d=-38.74% | Revisions=-25% | Analysts=2
EPS current Year (2027-03-31): EPS=-2.78 | Chg30d=-43.83% | Revisions=-25% | GrowthEPS=+17.7% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-1.37 | Chg30d=-18.50% | Revisions=+40% | GrowthEPS=+50.9% | GrowthRev=+228.8%
[Analyst] Revisions Ratio: -12% (up=2, down=3)